Track Eliem Therapeutics Inc Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Eliem Therapeutics Inc Common Stock ELYM · Stock Open Eliem Therapeutics Inc Common Stock in new tab

5.11 USD
Add to portfolio
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Eliem Therapeutics Inc Common Stock (ELYM)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Eliem Therapeutics Inc Common Stock Logo Eliem Therapeutics Inc Common Stock Analysis (ELYM)

United States Health Care Official Website Stock

Is Eliem Therapeutics Inc Common Stock a good investment? Eliem Therapeutics Inc Common Stock (ELYM) is currently trading at 5.11 USD.

Investor FAQ

Does Eliem Therapeutics Inc Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Eliem Therapeutics Inc Common Stock?

Eliem Therapeutics Inc Common Stock is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

Company Profile

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.

Exchange Ticker
US CLYM
NMS (United States) ELYM
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion